REG - Ergomed plc - Block listing application

ErgomedAnnouncement

27/06/2018 11:55

RNS Number : 7744S
Ergomed plc
27 June 2018
 


PRESS RELEASE
FOR IMMEDIATE RELEASE
 
 
Block listing application
 
London, UK - 27 June 2018: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a company focused on providing specialised services to the pharmaceutical industry, announces that an application has been made to the London Stock Exchange for a block listing of securities in respect of 1,800,000 ordinary shares of £0.01 each (the 'New Ordinary Shares') to be admitted to trading on AIM.
 
The New Ordinary Shares will be issued from time to time in order to satisfy the exercise of share options granted under the Ergomed plc Share Incentive Plan. It is expected that admission will become effective on 2 July 2018.
 
When issued, the New Ordinary Shares will be credited as fully paid and will rank pari passu in all respects with the existing ordinary shares of £0.01 each in the capital of the Company ('Ordinary Shares').
 
The Company will notify as required when there are changes to the issued share capital of the Company, and these figures may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
 
ENDS
 
Enquiries:
 



Ergomed plc


   Tel: +44 (0) 1483 503 205




Stephen Stamp (Chief Executive Officer)


















Numis Securities Limited


Tel: +44 (0) 20 7260 1000




Michael Meade / Freddie Barnfield (Nominated Adviser)








James Black (Joint Broker)


















N+1 Singer


Tel: +44 (0) 20 7496 3000




Aubrey Powell (Joint Broker)


















Consilium Strategic Communications - for UK enquiries


Tel: +44 (0) 20 3709 5700




Chris Gardner / Mary-Jane Elliott / Ivar Milligan


















MC Services - for Continental European enquiries


Tel: +49 211 5292 5222




Anne Hennecke







 
 
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: http://ergomedplc.com
 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ALSKMGZVGNGGRZM